GlassScriptPhysician profile
Brett Wilson
NPI 1053928804
$2,744.92
in general payments reported to CMS, 2019-2025
28 companies · $500 in 2025
The $500 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $878 · 2023: $567 · 2024: $799 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,866.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $541.82 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $258.52 | 2022 | |
| Abbvie INC. | $223.94 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $222.94 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $197.96 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Corcept Therapeutics | $172.11 | 2022-2025 | Korlym |
| Amgen INC. | $118.62 | 2022-2025 | Repatha, Otezla, Otezla |
| Stryker Corporation | $97.45 | 2024 | Vsp System, Vsp Cranial, Na, Adherus Autospray Dural Sealant |
| Exact Sciences Corporation | $97.30 | 2024-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $88.28 | 2022 | |
| Novartis Pharmaceuticals Corporation | $84.43 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $78.39 | 2022 | |
| Pfizer INC. | $71.01 | 2022-2025 | |
| Dexcom, INC. | $57.20 | 2022-2023 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $50.68 | 2023-2024 | Gemtesa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $45.80 | 2022-2023 | Trelegy Ellipta, Shingrix |
| Merck Sharp & Dohme LLC | $41.40 | 2025 | Capvaxive, Gardasil 9 |
| Inspire Medical Systems, INC. | $41.19 | 2024 | Inspire |
| Insulet Corporation | $38.98 | 2023 | Omnipod |
| Xeris Pharmaceuticals, INC. | $38.43 | 2023-2025 | Gvoke Hypopen |
| Averitas Pharma INC. | $34.73 | 2023 | Qutenza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.49 | 2022-2023 | Jardiance |
| Edwards Lifesciences Corporation | $20.76 | 2025 | |
| Nevro Corp. | $20.32 | 2023 | Senza |
| Tempus Ai, INC | $20.13 | 2024 | |
| Horizon Therapeutics Plc | $19.73 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.35 | 2024 | Voquezna |
| Antares Pharma, INC. | $12.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.